


CSL Behring


Biotherapies for Life®

Fact Sheet CSL Behring




2016/2017

CSL Behring Sales \$5.8 Billion



By Region

- 45.8% North America
- 29.1% Europe
- 16.6% Asia-Pacific
- 8.5% Intercontinental



By Therapeutic Area

- 46.8% Immunology
- 19.0% Hematology
- 34.2% Specialty Care

Major Product Approvals

CSL Behring has received a total of 31 regulatory approvals for new products or indications since 2004.

CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies to treat people with life-threatening medical conditions.

We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.

Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop and dependably deliver innovations that patients and providers want.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), is headquartered in Melbourne, Australia.

For more information visit www.cslbehring.com, and follow us on [@CSLBehring](http://www.Twitter.com/CSLBehring) and www.linkedin.com/company/csl-behring.

Employees: 16,000+ employees worldwide

Operational Headquarters: King of Prussia, Pennsylvania, USA

Plasma Collection: CSL Plasma is one of the world's largest plasma collection organizations. The company operates more than 170 collection centers.

Manufacturing: Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; Kankakee, Illinois, USA; Wuhan, China

Therapeutic Areas

Immunology: Immunodeficiency and autoimmune diseases, such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura and Guillain-Barré syndrome, and to prevent hemolytic disease of the newborn and cytomegalovirus infection in patients following solid organ transplant

Hematology: Coagulation or bleeding disorders, including hemophilia and von Willebrand disease

Specialty: Alpha-1 antitrypsin deficiency (hereditary emphysema), hereditary angioedema and for warfarin reversal, wound healing, shock, burns, sepsis and during surgery

Media Inquiries

Natalie de Vane | Corporate Media Inquiries | +1-610-878-4468 | Natalie.deVane@cslbehring.com

Chris Florentz | Corporate Media Inquiries | +1-610-878-4316 | Christopher.Florentz@cslbehring.com

Greg Healy | (Products: Hemophilia, Coagulants) | +1-610-878-4841 | Greg.Healy@cslbehring.com

Jennifer Purdue | (Products: Immunoglobulins, Specialty Products) | +1-610-878-4802 | Jennifer.Purdue@cslbehring.com

Bernard Ronchi | CSL Ltd. Investor Relations | +613-9389-3470 | Bernard.Ronchi@csl.com